Johns Hopkins and Kaiser Permanente Research Collaboration Grant
July 13, 2018
Kaiser Permanente and Johns Hopkins Medicine Research Collaboration
Committee is actively requesting research proposals to foster
collaborative research between the two institutions and address complex
and intriguing healthcare and clinical questions vexing our health
systems. Specifically, they are looking for research proposals that
are aligned with both organizations' strategies and present opportunities
to prove the synergy of the Kaiser Permanente/Johns Hopkins collaboration.
The hope is to identify and fund proposals that accomplish seminal
research utilizing the unique capabilities that only two such organizations
as Kaiser Permanente and Johns Hopkins have.
Broadly, the goal is to support collaborative epidemiologic, health
services and related clinical research to be conducted jointly by
Kaiser Permanente and Johns Hopkins researchers. The review panel
(the Kaiser Permanente/Johns Hopkins Research Collaboration Committee,
"RCC") will consider a wide array of research proposals
ranging from analyzing EMR data, developing clinical research registries,
implementing safety and quality improvement research projects and
large collaborative studies, and conducting comparative effectiveness
trials. The proposals have limited funding (up to $75,000 for 12 months;
non-renewable), so the goal is likely to fund pilot work for larger
and more complex research proposals later.
Funding for Prostate Cancer Research
DEADLINE: Monday, July 16, 2018 by 5:00PM (EST)
Funding is available to support multidisciplinary
research in prostate cancer through the Patrick C. Walsh Prostate Cancer
Research Fund, the SPORE Development Research Program (DRP), and the
SPORE Career Enhancement Program (CEP). Awards are for one year and
a maximum of $100,000, with an exception for the SPORE CEP. The CEP
awards will be given as 2-year awards at $50,000 per year. Investigators
will be allowed to request a 1-year no cost extension at the end of
the award period with proper scientific justification.
Funding is open to all JHU affiliated faculty.
Partnership with a Brady Urological Institute faculty member is highly
encouraged, but not required. An emphasis will be placed on funding
research with a high priority given to project innovation as well as
collaboration with basic science, data science, and engineering faculty.
Funds are to be used for supporting the proposed
research application, however they should not be used to support PI
salary. Awardees will be notified in mid to late August (2018). The
award period will be from September 1, 2018 through August 31, 2019.
For more information, visit the website at http://urology.jhu.edu/PCW/index.php.
Applications should be submitted using the application
portal at https://public.onc.jhmi.edu/pilotProjects/
by Monday, July 16, 2018. Please be certain that you are
submitting an application for the Patrick C. Walsh Prostate Cancer Research
Questions regarding the application process should be directed to David "Brandy" Yeater via email (email@example.com).
Internal deadline: July
The Searle Scholars Program supports the independent
research of 15 outstanding early-career scientists each year who have
recently been appointed as assistant professors on a tenure-track appointment.
The program is primarily interested in the potential of applicants to
make innovative and high-impact contributions to research over an extended
period of time. Applicants are expected to be pursuing independent research
careers in biochemistry, cell biology, genetics, immunology, neuroscience,
pharmacology, and related areas in chemistry, medicine, and the biological
sciences. The Searle Scholars Program does not ordinarily support purely
clinical research but has supported research programs that include both
clinical and basic components.
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.